Trials / Completed
CompletedNCT01024192
Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA
Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) Administered on as Needed Basis in Patients With Chronic insomNIA
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Primary Objective: To evaluate the efficacy and safety of the use of Stilnox CR in Mexican patients with chronic insomnia at the prescription conditions of daily practice Secondary Objective: To evaluate the satisfaction of the patient with chronic insomnia with Stilnox CR over an as needed basis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZOLPIDEM SL800750 | Pharmaceutical form: Zopidem 12.5 mg tablets Route of administration: Oral Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights) |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2009-12-02
- Last updated
- 2010-10-05
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT01024192. Inclusion in this directory is not an endorsement.